Aficamten (CK-274): A Next-Generation Cardiac Myosin Inhibitor for Research and Development

Discover Aficamten (CK-274), a cutting-edge cardiac myosin inhibitor designed for the research and development of advanced cardiovascular therapies. Explore its potential for treating hypertrophic cardiomyopathy and its benefits for pharmaceutical innovation.

Get a Quote & Sample

Key Advantages of Sourcing Aficamten

Exceptional Purity & Quality

Our Aficamten, supplied with a purity exceeding 99% (tested via HPLC, UV, TLC), meets the stringent demands of pharmaceutical R&D. As a reputable manufacturer, we guarantee lot-to-lot consistency, critical for reliable experimental results in your drug discovery program.

Facilitating Cardiac Research

Aficamten (CK-274) is a next-generation cardiac myosin inhibitor vital for research into hypertrophic cardiomyopathy (HCM). By understanding its role in regulating cardiac contractility, researchers can accelerate the development of new therapeutic strategies. We are a key supplier for researchers worldwide.

Cost-Effective Procurement

We offer competitive price points for Aficamten, making it accessible for both academic institutions and pharmaceutical companies. Buy Aficamten in China to optimize your procurement budget while maintaining high quality standards for your projects.

Applications of Aficamten in Pharmaceutical R&D

Hypertrophic Cardiomyopathy (HCM) Research

Aficamten is a crucial tool for understanding and developing treatments for HCM. Its mechanism of action targets the underlying sarcomeric dysfunction, making it a prime candidate for further clinical investigation. Researchers can purchase this intermediate to explore its therapeutic potential.

Cardiac Myosin Inhibition Studies

Investigate the precise effects of cardiac myosin inhibition on myocardial function. Aficamten serves as a reliable chemical probe for exploring pharmacodynamic and pharmacokinetic relationships, essential for preclinical and clinical drug development. Inquire about Aficamten price today.

PK/PD Relationship Studies

The optimized pharmacokinetic profile of Aficamten, including its predicted human half-life for once-daily dosing, makes it ideal for detailed pharmacokinetic/pharmacodynamic (PK/PD) relationship studies. Our product enables thorough evaluation for pharmaceutical pipelines.

Drug Discovery and Development

Utilize high-purity Aficamten as a foundational compound in your drug discovery pipeline. As a dedicated supplier, we ensure the quality and availability needed to advance your research from early-stage discovery to potential clinical trials. Request a quote for bulk purchases.